The company's new Emdolten drug is a day-to-day board in the form of ARV medication that is resistant to drug resistant that often develops with older HIV treatments.
Logo Aspen Pharmacare. Photo: After Delivery.
JOHANNESBURG – South African Aspen Pharmacare Drug on Monday launched deuflyg tablets for treating HIV in the country where the virus is most common.
The company's new Emdolten drug is a day-to-day board of dolomegravir, antiretroviral drug resistant drug resistant that often develops with older HIV treatments, says Aspen.
The drug also includes lamivudine and tenofovir disoproxil fumarate alongside dolutegravir.
In May, the South African Health Products Regulatory Authority and the Warning Medicines Agency announced a warning to doctors not to prescribe dolutegravir for women trying to get pregnant.
This followed preliminary data from a study in Botswana, which discovered four causes of celestial tube defects in babies born to mothers who became pregnant when taking the drug.
The drug is seen in the Tivicay and Triumeq brand remedies, sold by the majority of the ViiV Healthcare unit GlaxoSmithKline.
Aspen, who led to the development and manufacture of generic antiretrovirals (ARV) in South Africa, said the use of dolutegravir is safe for men, women who do not have the age of children and girls who are kidnapped by contraception, adding These groups represent more than 70% of HIV patients.
"The fact that he (Emdolten) is registered makes SAHPRA comfortable that it is safe to take to the public," said Stavros Nicolaou, Aspen's strategic trading operator, at Reuters , referring to the South African Health Products Regulatory Authority.
The Aspen Stavudine company launched its first generic ARV drug in August 2003 – at a time when the country was disrupting a high HIV infection rate.
South Africa has 19% of the global number of people living with HIV, 15% of new infections and 11% of AIDS-related deaths, said the AIDS agency of the Nations United on its website.
There is no HIV / AIDS prevention vaccine. Existing treatments help patients control the disease only, but the rapidly cheated virus has been a challenge to the medical community because it often develops resistance to existing medicines.